Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Biomedical Signal Processing and Control
|
June 26, 2023
Optimized DEC: An effective cough detection framework using optimal weighted Features-aided deep Ensemble classifier for COVID-19
Muhammad Awais, Abhishek Bhuva, Dipen Bhuva, et al.
BMC Cancer
|
August 18, 2025
A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
Nihanthy D Sreenath, Suresh Pandalanghat, Amul Kapoor, et al.
South Asian Journal of Cancer
|
December 23, 2020
Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study
Amol Patel, Dharmesh Soneji, Harinder Pal Singh, et al.
Clinical Genitourinary Cancer
|
December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
Fernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Minerva Urology and Nephrology
|
April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)
Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Biomedical Signal Processing and Control
|
June 26, 2023
Optimized DEC: An effective cough detection framework using optimal weighted Features-aided deep Ensemble classifier for COVID-19
Muhammad Awais, Abhishek Bhuva, Dipen Bhuva, et al.
BMC Cancer
|
August 18, 2025
A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort
Nihanthy D Sreenath, Suresh Pandalanghat, Amul Kapoor, et al.
South Asian Journal of Cancer
|
December 23, 2020
Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study
Amol Patel, Dharmesh Soneji, Harinder Pal Singh, et al.
Clinical Genitourinary Cancer
|
December 13, 2023
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
Fernando Sabino Marques Monteiro, Ondřej Fiala, Francesco Massari, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
Frontiers in Immunology
|
May 6, 2026
Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1)
Evelyn L Beas-Lozano, Sarah Scagliarini, Paola I Valdez-Sandoval, et al.
Cancer Immunology, Immunotherapy : CII
|
June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Minerva Urology and Nephrology
|
April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)
Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology
|
September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)
Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Page
of 2